Vistagen provides corporate update and reports fiscal 2024 second quarter financial results

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended september 30, 2023. “vistagen achieved multiple important milestones in recent months, significantly advancing our innovative.
VTGN Ratings Summary
VTGN Quant Ranking